Therefore, in this study, we believe that in ARID1A-deficient tumor cells, nPD-L1 is signaled to activate RASGEF1A and the Ras signaling pathway, ultimately leading to resistance to Osimertinib. The gene discussed is RASGEF1A; the disease is neoplasm.